You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃華醫藥(002107.SZ):上半年淨利潤1108萬元 同比下降70.21%
格隆匯 08-02 19:24

格隆匯8月2日丨沃華醫藥(002107.SZ)公佈半年度報吿,營業收入3.95億元,同比下降19.73%,淨利潤1108萬元,同比下降70.21%,扣非淨利潤982.87萬元,同比下降72.46%,基本每股收益0.02元。

沃華醫藥目前擁有藥品批准文號162個,其中獨家產品15個,並有93個產品進入了《國家基本醫療保險、工傷保險和生育保險藥品目錄(2023年版)》,43個產品進入《國家基本藥物目錄(2018年版)》。獨家產品中,沃華?心可舒片、骨疏康膠囊/顆粒、荷丹片/膠囊、腦血疏口服液市場基礎雄厚、療效顯著、使用安全,發展潛力巨大,在細分治療領域的品牌影響力不斷提升,是公司集中優勢資源、聚焦細分市場、重點打造的“四大獨家醫保支柱產品”。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account